- Maggio 2024

Ganz PA, Bandos H, Španić T, et al.

Patient-reported outcomes in olympia: a phase III, randomized, placebo-controlled trial of adjuvant olaparib in gBRCA1/2 mutations and high-risk human epidermal growth factor receptor 2-negative early breast cancer

J Clin Oncol 2024;42(11):1288-1300

robert.butucaru@medfyle.com Maggio 2024

Leggi abstract | Scarica ppt

---

Leon-Ferre RA, Jonas SF, Salgado R, et al.

Tumor-infiltrating lymphocytes in triple-negative breast cancer

JAMA 2024;331(13):1135-1144

robert.butucaru@medfyle.com Maggio 2024

Leggi abstract | Scarica ppt

---

Alaeikhanehshir S, Ajayi T, Duijnhoven FH, et al.

Locoregional breast cancer recurrence in the European Organisation for Research and Treatment of Cancer 10041/BIG 03-04 MINDACT trial: analysis of risk factors including the 70-gene signature

J Clin Oncol 2024;42(10):1124-1134

robert.butucaru@medfyle.com Maggio 2024

Leggi abstract | Scarica ppt

---

de Boniface J, Filtenborg Tvedskov T, Rydén L, et al.

Omitting axillary dissection in breast cancer with sentinel-node metastases

N Engl J Med 2024;390(13):1163-1175

robert.butucaru@medfyle.com Maggio 2024

Leggi abstract | Scarica ppt

---

Geyer CE Jr, Blum JL, Yothers G, et al.

Long-term follow-up of the anthracyclines in early breast cancer trials (USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 [NRG Oncology])

J Clin Oncol 2024;42(12):1344-1349

robert.butucaru@medfyle.com Maggio 2024

Leggi abstract | Scarica ppt

---

Williams AD, Ruth K, Shaikh SS, et al.

Should patients with hormone receptor-positive, HER2-negative breast cancer and one or two positive sentinel nodes undergo axillary dissection to determine candidacy for adjuvant abemaciclib?

Cancer 2024;130(7):1052-1060

robert.butucaru@medfyle.com Maggio 2024

Leggi abstract

---

Shah M, Lingam H, Gao X, et al.

US Food and Drug Administration Approval Summary: elacestrant for estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated advanced or metastatic breast cancer

J Clin Oncol 2024;42(10):1193-1201

robert.butucaru@medfyle.com Maggio 2024

Leggi abstract

---

Tarantino p, Ajari O, Graham N, et al.

Evolution of HER2 expression between pre-treatment biopsy and residual disease after neoadjuvant therapy for breast cancer

Eur J Cancer 2024;201:113920

robert.butucaru@medfyle.com Maggio 2024

Leggi abstract

---

Botticelli A, Caputo R, Scagnoli S, et al.

Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: the DE-REAL study

Oncologist 2024;29(4):303-310

robert.butucaru@medfyle.com Maggio 2024

Leggi abstract

---

Akkoc Mustafayev FN, Shukla MA, Lanier A, et al.

Survival outcomes of patients with HER2/neu-positive breast cancer with germline BRCA mutations

Cancer 2024;130(9):1600-1608

robert.butucaru@medfyle.com Maggio 2024

Leggi abstract

---

Haiderali A, Huang M, Pan W, et al.

Pembrolizumab plus chemotherapy for first-line treatment of advanced triple-negative breast cancer

Future Oncol 2024 Apr 10 doi: 10.2217/fon-2023-0301. Epub ahead of print.

robert.butucaru@medfyle.com Maggio 2024

Leggi abstract

---

Bardia A, Krop IE, Kogawa T, et al.

Datopotamab deruxtecan in advanced or metastatic HR+/HER2- and triple-negative breast cancer: results from the phase I TROPION-PanTumor01 study

J Clin Oncol 2024 Apr 23:JCO2301909. Epub ahead of print

robert.butucaru@medfyle.com Maggio 2024

Leggi abstract

---

Brantley KD, Rosenberg SM, Collins LC, et al.

Second primary breast cancer in young breast cancer survivors

JAMA Oncol 2024 Apr 11:e240286. Epub ahead of print

robert.butucaru@medfyle.com Maggio 2024

Leggi abstract

---

• ← Previous